First Wave BioPharma Shares Move Higher, Roth MKM Raises PT To $40
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma's stock price has increased following an updated price target from Roth MKM, which raised its PT to $40.

January 02, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM has raised the price target for First Wave BioPharma to $40, likely resulting in increased investor confidence and a higher stock price in the short term.
Analyst upgrades or positive changes in price targets are typically seen as bullish signals by the market, often leading to a short-term increase in the stock's price. Given that Roth MKM has set a significantly high price target for FWBI, this can be interpreted as a strong vote of confidence in the company's future performance, potentially attracting more investors and driving up the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100